Umbrella Labs Epitalon Peptide Documentation Update (May 25): Reference-Material Standardization for Research Pipeline Ahead of July 23-24 PCAC Review
Umbrella Labs announced Monday May 25 a documentation and traceability update for its Epitalon peptide reference material, provided strictly for laboratory developmental research use. The update is part of the company's standardization initiative focused on identity-field consistency, record continuity, and reproducibility — the same template Umbrella applied to Dihexa on May 19. Epitalon (Glu-Asp-Gly-Lys) is a four-amino-acid peptide originally derived from the bovine pineal gland by Vladimir Khavinson and studied as a senescent-cell modulator and telomerase activator. The peptide is on the FDA's PCAC review docket for July 23-24, 2026 — Day 2 alongside Emideltide/DSIP and Semax — for potential 503A bulks-list inclusion. Reference-material standardization across the research-peptide supply chain is the soft regulatory signal that compounding pharmacies and supply networks are preparing for the PCAC review window.